Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

Sponsor
Chinese PLA General Hospital
Study ID
NCT02490176
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Liraglutide were taken daily for 7 days
  • placebo — DRUG
    Placebo were taken daily for 7 days

Study Details

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and GLP-1 analogues were recently introduced for the treatment of acute myocardial infarction. The investigators planned to evaluate the effects of liraglutide on haemodynamic parameters in patients with heart failure.

Key Dates

Start date
Jul 31, 2015
Status verified
Feb 2016
Primary completion
Jul 31, 2016
Completion
Jul 31, 2016

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: GLP-1 group
    drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
  • Placebo Comparator: Control group
    drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.

Primary Outcome Measure

a change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology [ Time Frame: 7 days after treatment ]

Central Contacts

Related Studies